ClinicalTrials.gg
WithdrawnNCT06904274SUNFLOWERUpdated Jul 30, 2026

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

A Phase 3 interventional study of BAY865028 and Medroxyprogesterone acetate in Endometrial Hyperplasia, sponsored by Bayer. Withdrawn at 38 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Bayer cancelled study 22923 due to enrollment challenges, including difficulties identifying eligible patients, participation requirements, and site burden. The decision was unrelated to safety and does not change Mirena's benefit-risk profile.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Endometrial Hyperplasia with a site in United States — 10 open to participants now, 16 under way, none of them phase 3. Endometrial Hyperplasia · United States.

Enrollment
23rd of 23
0 · median 48
Started
2025
the only one that year
Phase 3
3 of 29
none open now
Registered
22nd of 29
by date
Lead sponsor
1 of 29
Bayer

Among the 29 studies in Endometrial Hyperplasia with a site in United States, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 3, and was the 22nd registered.

Endometrial Hyperplasia

110 studies on the registry are indexed under Endometrial Hyperplasia; 38 are open to participants now.

Browse Endometrial Hyperplasia studies →

Open to participants now

10 of the 29 studies in Endometrial Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Endometrial Hyperplasia studies recruiting now, 9 (43%) set no upper age limit and 11 (52%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Endometrial Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).

Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.

Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need.

The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.

In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.

The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population.

For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA.

The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.

Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site.

Participants will visit the study clinic:

  • once before the treatment starts
  • 3 times with a gap of 3 months between the visits during the treatment
  • then 1 more time after the treatment ends

During the study, the doctors and their study team will:

  • check participant's health by performing tests such as blood and urine tests
  • perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.
  • take samples of womb (endometrial) lining
  • ask the participants questions about how they are feeling and what adverse events they are having

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

03

Conditions studied

  • Endometrial Hyperplasia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post-menarchal women (≥18 years) at the time of signing the .
  • Women with confirmed NAEH independent of their parity or menopausal status. Endometrial samples will be obtained either at screening or no more than 42 days prior to the signing of the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results.
  • Congenital or acquired uterine or cervical anomaly including fibroids, or cervical stenosis that in the opinion of the investigator, would interfere with insertion and/or retention of the intrauterine system (i.e., if they distort the uterine cavity).
  • Use of any long-acting injectable sex-hormone preparations within 6 months prior to the start of study intervention, and /or short acting hormonal medication within 6 weeks prior to the start of study intervention.
  • Pregnancy
  • Participants with either known family or personal history of genetic predisposition to uterine, ovarian or colorectal cancers (e.g. Lynch syndrome).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Levonorgestrel (BAY865028, Mirena)

    Mirena will be inserted into the participant's uterus by the investigator on Day 1. At visit 4 (after 6 months) or if a participant discontinues her study participation prematurely, the Mirena will be removed by the investigator.

    Combination Product: BAY865028

  • Active comparator
    Oral progestin

    Participants will receive 10mg oral progestin once daily, preferably always at the same time of the day, until visit 4 (after 6 months).

    Drug: Medroxyprogesterone acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Complete Resolution (CR) of NAEH

    Complete Resolution will be evaluated as benign endometrium.

    Time frame: At 6 months

Secondary outcomes

  1. Recurrence of NAEH after CR

    Recurrence of NAEH on 3 months treatment free after CR at 6 months

    Time frame: At 3 months follow up after 6 months treatment

  2. Progression after CR

    Endometrial hyperplasia with atypia or endometrial cancer after 3 months treatment free follow up after CR at 6 months

    Time frame: At 3 months follow up after 6 months treatment

  3. Proportion of participants having hysterectomy

    Time frame: During treatment and 3 months follow up

  4. Diagnosis of "benign endometrium"

    Time frame: At 6 months of treatment followed by 3 month treatment-free follow up

  5. Number of participants with adverse events

    All AEs will be coded using the latest version prior to database lock of the Medical Dictionary for Regulatory Activities

    Time frame: From the signing of the informed consent form (ICF) up to 3 months after the last dose of study intervention

07

Study locations

38 sites
  • Velocity Clinical Research - Phoenix
    Phoenix, Arizona 85006, United States
  • Cornerstone Clinic for Women - Aldersgate
    Little Rock, Arkansas 72205, United States
  • Alliance Clinical West Hills
    West Hills, California 91307, United States
  • Sweet Hope Research Specialty, Inc. - Hialeah
    Hialeah, Florida 33016, United States
  • New Age Medical Research Corp.
    Miami, Florida 33186, United States
  • Entrust Clinical Research
    Palmetto Bay, Florida 33176, United States
  • Emerald Coast Clinical Research
    Panama City, Florida 32405, United States
  • Paramount Research Solutions | College Park Location
    Atlanta, Georgia 30327, United States
  • Office of Dr. Cindy Basinski, LLC
    Evansville, Indiana 47715, United States
  • Velocity Clinical Research - Lafayette
    Lafayette, Louisiana 70508, United States
  • Southern Clinical Research Associates
    Metairie, Louisiana 70001, United States
  • Omni Fertility and Laser Institute
    Shreveport, Louisiana 71118, United States
  • Revive Research Institute - Michigan - Women's Health
    Dearborn Heights, Michigan 48127, United States
  • Bosque Women's Care | Albuquerque, NM
    Albuquerque, New Mexico 87109, United States
  • Unified Women's Clinical Research - Centre OB/GYN
    Raleigh, North Carolina 27607, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • ClinOhio Research Services, LLC. | Columbus, OH
    Columbus, Ohio 43213, United States
  • OB/GYN Associates of Erie
    Erie, Pennsylvania 16507, United States
  • Chattanooga Medical Research, LLC. | Chattanooga, TN
    Chattanooga, Tennessee 37412, United States
  • Discovery Clinical Trials - Dallas
    Dallas, Texas 75230, United States
  • Biopharma Informatic - West Houston
    Houston, Texas 77043, United States
  • AIH Research- Broadway
    Pearland, Texas 77584, United States
  • The Ottawa Hospital, Riverside Campus - Department of Obstetrics, Gynecology and Newborn Care
    Ottawa, Ontario K1H 7W9, Canada
  • Mount Sinai Hospital Toronto | Gynecology
    Toronto, Ontario M5G 1Z5, Canada
  • Centres Investigation Clinique Mauricie
    Trois-Rivières, Quebec G8T 7A1, Canada
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality 100029, China
  • Peking Union Medical College Hospital CAMS
    Beijing, Beijing Municipality 100730, China
  • Chongqing Maternal and Child Health Care Hospital
    Chongqing, Chongqing Municipality 401147, China
  • Xiamen Maternity and Child Health Care Hospital - Gynecology Department
    Xiamen, Fujian 361003, China
  • The Third Affiliated Hospital of Southern Medical University - Gynecology Department
    Guangzhou, Guangdong 510630, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Tangshan Maternal and Child Health Care Hospital
    Tangshan, Hebei 063014, China
  • Nanjing Maternity and Child Health Care Hospital
    Nanjing, Jiangsu 210004, China
  • Nanjing Medical University (NMU) - The Second Affiliated Hospital
    Nanjing, Jiangsu 210011, China
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi 330006, China
  • Shaanxi Provincial People's Hospital
    Xi'an, Shaanxi 710068, China
  • Women and Children's Hospital, Qingdao University - Gynecology department
    Qingdao, Shandong 266034, China
  • Chengdu Women & Children's Central Hospital
    Chengdu, Sichuan 610091, China
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jun 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Apr 1, 2025
StartActual
Nov 24, 2025
Primary completionActual
Jun 17, 2026
CompletionActual
Jun 17, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06904274
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 1, 2025
Start date
Nov 24, 2025
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Jul 30, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion